Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity
Journal Title: The AAPS Journal - Year 2001, Vol 3, Issue 3
Abstract
Patients undergoing anticoagulation with heparin or low molecular weight heparin (LMWH) require a superior antidote that possesses more selective biological actions and a better safety profile than protamine. We had previously developed 2 low molecular weight protamine (LMWP) fractions (TDSP4 and TDSP5) from thermolysin-digested protamine as potential nontoxie, heparin-neutralizing agents. In this, the second article in this series, studies focused on in vitro evaluation of heparin/LMWH-neutralizing efficacy and putative toxicity. These LMWP fractions, particularly TDSP5, were effective and fully capable of neutralizing a broad spectrum of heparin-induced anticoagulant activities (ie, aPTT, anti-Xa, and anti-IIa activities). Additionally, these LMWP fractions could neutralize the activities of commercial LMWH. As assessed by the anti-Xa assay, TDSP5 was as effective as, although less potent than, protamine in reversing the activity of Mono-Embolex (molecular weight 5000–7000) and 2 other different sizes (molecular weight of 3000 and 5000 d) of LMWH preparations. Furthermore, compared with protamine, TDSP5 exhibited a much-reduced toxicity and thus an improved safety profile, as reflected by its reduced ability to activate the complement system and cross-react with the antiprotamine antibodies, which are 2 primary indices of protamine toxicity.
Authors and Affiliations
Li-Chien Chang, Jun Feng Liang, Hsiao-Feng Lee, Lai Ming Lee, Victor C Yang
Keywords
Related Articles
- EP ID EP682057
- DOI 10.1208/ps030318
- Views 95
- Downloads 0
Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity
Replacement therapy with exogenous recombinant factor VIII (rFVIII) to control bleeding episodes results in the development of inhibitory antibodies in 15% to 30% of hemophilia A patients. The inhibitory antibodies are m...
Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory
Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?
The analysis of biotherapeutics by ligand-binding assay (LBA) is associated with some unique challenges that are unlike those commonly encountered in chromatographic methods for chemically based small molecule drugs. Whi...
Quality by Design: Concepts for ANDAs
Quality by design is an essential part of the modern approach to pharmaceutical quality. There is much confusion among pharmaceutical scientists in generic drug industry about the appropriate element and terminology of q...
Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn
The online version of this article (doi:10.1208/s12248-012-9395-9) contains supplementary material, which is available to authorized users.